BioVectra Inc. Announces the Offer of High Quality, Fully Synthetic cGMP Cannabidiol (CBD) Active Pharmaceutical Ingredient (API)
Charlottetown, Prince Edward Island, Canada (March 17, 2019) – BioVectra Inc., a U.S. Food and Drug Administration- and Health Canada-inspected and approved Contract Development and Manufacturing Organization (CDMO), announces the offer of high quality, fully synthetic cGMP CBD API for clinical and commercial applications. BioVectra’s efficient cGMP CBD manufacturing process allows for the production of hundreds of kilograms, with the ability to scale-up to multi-metric ton quantities. This scale-up and supporting regulatory experience is a key competency for BioVectra, which can be applied to additional cannabinoid derivatives. Production is on-going for intermediate-scale batches, with process validation and submission of a Drug Master File to follow.
Located in Canada, BioVectra is uniquely positioned as a global supplier of synthetic cGMP CBD. The company can offer material supply, as well as product storage services as required.
BioVectra has a history of working in cannabinoids, dating back to the early 2000s, when it developed a supply of dronabinol. Building off its existing strengths in complex synthetic chemistry and natural product purifications, the company’s ability to manufacture synthetic cGMP CBD complements increased market demand. BioVectra looks forward to continuing to supply its current and new customers with this pharmaceutically important compound.
For more information, please contact BioVectra at email@example.com or 866-883-2872 to discuss your CBD requirements.
BioVectra is a CDMO that serves global pharmaceutical and biotech companies with full-service cGMP outsourcing solutions for intermediates and active pharmaceutical ingredients. An innovative and reliable service partner with a strong regulatory history, BioVectra has over 45 years of experience specializing in:
- cGMP Microbial Fermentation
- Complex Chemistry – High Potency APIs
- Formulation Development
For more information about BioVectra, please visit www.biovectra.com.
Fahim Naeem, Business Development Manager